Circio Holding ASA (CRNA) - tidl: Targovax (TRVX) 1 4

[Birgitte]

16,4% er andelen aksjer til Atlas.

83,6% eies av andre.

[TekBot]

Circio enters fully funded feasibility study with major global pharmaceutical corporation

Oslo, Norway, 18 November 2025 – Circio Holding ASA (OSE: CRNA), a
biotechnology company developing novel circular RNA expression technology for
gene and cell therapy, today announces that it has entered an agreement with
…

Vis børsmeldingen

one of the major global pharmaceutical corporations to conduct a feasibility
study of circVec-enhanced gene therapy.

The feasibility study involves testing of Circio’s circVec circular RNA
expression technology for delivery with AAV vectors in a specific therapeutic
area. The project will be performed by Circio and is fully funded by the
pharmaceutical company. The agreement does not include any downstream rights
or obligations on either party.

“Following the presentation of pre-clinical data showing up to 40-fold
advantage for circVec vs. conventional AAVs at major scientific conferences in
2025, Circio has attracted growing interest from a range of prospective gene
therapy collaboration partners,” said Dr. Erik Digman Wiklund, CEO of Circio.
“Today, Circio has entered its first feasibility study with a major
pharmaceutical company. This feasibility study will allow us to broaden the
scope of our AAV gene therapy evaluation and serves as an important
endorsement of the potential of the circVec platform. We are in parallel
exploring opportunities to further expand our gene therapy activities through
additional partnerships in other therapeutic areas where circVec has shown
promise in pre-clinical studies.”

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 40-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology
program, TG01, through cost-efficient external academic and industry
collaborations. TG01 targets RAS-mutated cancers and is being tested in two
clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine
adjuvanted by STIMULON QS-21 licensed from Agenus Inc.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR article 17 and section 5-12 of the Norwegian Securities
Trading Act. The information was submitted for publication at 2025-11-18 07:00
CET.

This stock exchange announcement was published by Mats Hermansen, VP Finance,
on behalf of the Company, at the time and date stated above in this
announcement.

Kilde

[Bompiole]

Oii og dette var berre ett av skudda på mål rekner eg med.Gler meg til fortsettelsen rekner med resultater etter 3/6 mnd og kva skjer da ved gode resultater?Er vel en del grunner til at partner er anonym. Rekner med mere snadder på mandag.Circio begynder virkelig å bli et meget interessant selskap

[Den.nye.vinen]

@TekBot

We are in parallel
exploring opportunities to further expand our gene therapy activities through
additional partnerships in other therapeutic areas where circVec has shown
promise in pre-clinical studies.”

Sounds good

[Bompiole]

rekner med det blir begivenhetsrike 6 mnd framover

[Baerntis]

En av de 2 ukjente fra 1H-2025 ? Not in the money yet. Litt skuffende kjenner jeg.

"major global pharmaceutical corporation”, peker mot en partner som har:

• pipeline med AAV-programmer
• interesse for payload/technology licensing
• ressurs til å finansiere preklinisk testing (feasibility)
• global markedsposisjon

BP eller GTC ?

[Bompiole]

tja dekker jo lønn,lab leige,og alt annet av kostnader.Resultata som virkelig gjorde vei i vellinga kom vel ikkje før i August og mulig vi får forbedra resultat på mandag??Tar tid å forhandle fram en avtale som involverer upfront 6/12 mnd

[aborum]

Meget spændende. Men … vi mangler stadigvæk en løsning på finansieringen af selskabet.

Der kommer mere info om dette fredag.

[JUBA]

@TekBot

ircio enters fully funded feasibility study with major global pharmaceutical corporation

Oslo, Norway, 18 November 2025 – Circio Holding ASA (OSE: CRNA), a

biotechnology company developing novel circular RNA expression technology for
gene and cell therapy, today announces that it has entered an agreement with
…

Vis børsmeldingen

one of the major global pharmaceutical corporations to conduct a feasibility
study of circVec-enhanced gene therapy.

The feasibility study involves testing of Circio’s circVec circular RNA
expression technology for delivery with AAV vectors in a specific therapeutic
area. The project will be performed by Circio and is fully funded by the
pharmaceutical company. The agreement does not include any downstream rights
or obligations on either party.

“Following the presentation of pre-clinical data showing up to 40-fold
advantage for circVec vs. conventional AAVs at major scientific conferences in
2025, Circio has attracted growing interest from a range of prospective gene
therapy collaboration partners,” said Dr. Erik Digman Wiklund, CEO of Circio.
“Today, Circio has entered its first feasibility study with a major
pharmaceutical company. This feasibility study will allow us to broaden the
scope of our AAV gene therapy evaluation and serves as an important
endorsement of the potential of the circVec platform. We are in parallel
exploring opportunities to further expand our gene therapy activities through
additional partnerships in other therapeutic areas where circVec has shown
promise in pre-clinical studies.”

[JUBA]

Dette innlegget ble rapportert og er midlertidig skjult.

[Rockzolid]

Dette er helt sjukt og knall bullish.

Mitt kursmål kr 3 (200%) i løpet av de neste par dagene. De følger deretter opp med presentasjon/webcast på mandag der vi blant annet får vite hvem de har avtale med.

Tipper vi passerer kr 4 etter webcast på mandag/tirsdag. Kr 4 vil prise selskapet til ca kr 560 mill som er helt innafor etter disse nyhetene.

[Birgitte]

Et viktig steg videre, Big Pharma snuser på circVec og bruker cash. Et sterkt kvalitetsstempel og vesetlig cashflow med sign on fee???

[Baerntis]

Kanskje lett og undervurdere hva dette egentlig betyr når det gjelder det finansielle. Hvem skriver under på en slik avtale når Circio står på kanten av egen runway og må overleve de neste 9-12 månedene ? Så hvordan er avtalen strukturert - upfront+milextones, milestones, cost covering ? Eller hva annet ligger i bunn som har overbevist BP ? om at selskapet faktisk kan gjennomføre studien ?

[aol]

Circio inngår samarbeidsavtale med «global farmagigant»

[Pk2k]

@Baerntis

Eller hva annet ligger i bunn som har overbevist BP ? om at selskapet faktisk kan gjennomføre studien ?

De betaler for studien

[Baerntis]

@Pk2k

De betaler for studien

Skjønner det, men den er neppe ment å finansiere selskapet de neste 12 månedene.

[Pk2k]

Kommende emisjon / videre lån fra Atlas ligger i kortene, missforstå meg rett, dagens melding er veldig bra men gir ingen runway til selskapet som du selv nevner.

[Baerntis]

@Pk2k

videre lån fra Atlas

Kan bety det, men da er det ikke mye selskapet faktisk trenger for å runde Q2-2026. Burde jo være mulig med en rettet emisjon nå. Uten alt for mye utvanning. Denne avtalen alene burde løfte MCAP 2-3X.

[Takk]

Nå ligger de årlige kostnadene til Circio på nivå med en grei lederlønn, så er ikke så mye. Om de kun fokuserer på aktivitet som er dekket gjennom dette er utgiftene utenom neglisjerbare. Pluss. Det kommer mer her.

Dette er de største og beste nyhetene for norsk bio på mange år

[Bompiole]

noen som har tilgang og kan dele?

Circio inngår samarbeidsavtale med «global farmagigant»